Journal Editor Perspectives

Slides:



Advertisements
Similar presentations
When Should a Clinical Trial Design with Pre-Stratification be Used? Group 1.
Advertisements

5S CLÍNICA MÉDICA (MH) 306 A. 5S CLÍNICA MÉDICA (MH) 306 B.
How does the process work? Submissions in 2007 (n=13,043) Perspectives.
Reading and evaluating the scientific and medical literature Robert Silbergleit, MD Department of Emergency Medicine.
Health Education and health promotion in Norwegian national curriculum Health Promotion is part of Section 9a in the Education Act, –“All pupils in primary.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Decreasing Hospital LOS for Bronchiolitis Sandweiss DR, Mundorff MB, Hill T, et al.
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
1 Lecture 20: Non-experimental studies of interventions Describe the levels of evaluation (structure, process, outcome) and give examples of measures of.
Sarah Struthers, MD March 19, 2015
Title Name Institute. Background -1 (Main problem)
1 EPI235: Epi Methods in HSR April 17, 2007 L5 Program Evaluation with Longitudinal Data 1: Applications (Dr. Schneeweiss) Various examples of applications.
TOWARDS RECOVERY CLINICS Patient Care. Community Fit. An Integrated Approach to Comprehensive Treatment.
Comparative Effectiveness Research : Rethinking Therapeutic Evaluation in Chronic Diseases Ph Ravaud.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Fundoplication at the Time of Gastrostomy Barnhart DC, Hall M, Mahant S, et al. Effectiveness.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Intermittent vs Continuous Pulse Oximetry McCulloh R, Koster M, Ralston S, et al.
The Opioid Addiction Treatment Database: Using administrative health data to conduct socially accountable research in the North Joseph K. Eibl, PhD and.
Improving Transitions of Care from Hospital to Home: A Health Care Reform Priority Gina Gill Glass, MD, FAAFP Barbara J. Roehl, MD, MBA, CAQ Geriatrics.
Presentation Developed for the Academy of Managed Care Pharmacy
Methodological Issues in Implantable Medical Device(IMDs) Studies Abdallah ABOUIHIA Senior Statistician, Medtronic.
Clinical Trials for Comparative Effectiveness Research Mark Hlatky MD Mark Hlatky MD Stanford University January 10, 2012.
Secondary Analysis of Clinical Trials Data – A Biostatistician’s Experience Gui-shuang Ying, PhD Center for Preventive Ophthalmology and Biostatistics.
The Dental Quality Alliance (DQA) Overview and Work of the DQA
My Experiences as an FDA Statistician
Clinical Trial Design for Second Generation TAVI - Academic View
Heparin Should be the First-line Therapy for Patients with ACS/AMI
Introduction.
Brady Et Al., "sequential compression device compliance in postoperative obstetrics and gynecology patients", obstetrics and gynecology, vol. 125, no.
5 Different Observational Datasets: Pros & Cons
Research using Registries
Hassan El Solh, MD CMO, AUBMC Director July 10, 2017
Stephen Joseph Galli, MD  Journal of Allergy and Clinical Immunology 
Clinicaltrials.gov Update
CLINICAL PROTOCOL DEVELOPMENT
Case Studies in Big Data and Analysis
Journal Club Notes.
ASSENT-3 PLUS 1,639 patients with STEMI Treatment Group A
Deputy Director, Division of Biostatistics No Conflict of Interest
Randomized Trials: A Brief Overview
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Erica Takai, PhD for Andrew Farb, M.D.
Cluster Randomized Trials
O’Connor Efficacy and Safety of Exercise Training as a Treatment Modality in Patients With Chronic Heart Failure: Results of A Randomized Controlled.
Crucial Statistical Caveats for Percutaneous Valve Trials
Hadassah University Hospital
Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018
Pilot Studies: What we need to know
Systematic Review (Advanced_Course_Module_6_Appendix)
Tim Auton, Astellas September 2014
Dr Peter Groves MD FRCP Consultant Cardiologist
کتابهای تازه خریداری شده فن آوری اطلاعات سلامت 1397
Expert Medical Opinion Program
FDA Sentinel Initiative
Development Plans: Study Design and Dose Selection
Main inclusion criteria)
Expert Medical Opinion Program
کتابهای خریداری شده فن آوری اطلاعات سلامت 1397
IMPACT OF PHARMACIST DELIVERED CARE IN THE COMMUNITY PHARMACY SETTING
The CIT Model: Can We Call It Evidence-Based?
Improving the Safety and Quality of Inter-hospital Transfer for Nontraumatic Intracranial Hemorrhage Ross Littauer, MD; Michael Yip, MD; John Sather, MD;
Regulatory Perspective of the Use of EHRs in RCTs
Lack of Confidence Interval Reporting in Dermatology: A Call to Action
Final best possible medication history (BPMH) protocol design after multiple plan–do–study–act at an academic urban safety net hospital. EHR, electronic.
Systematic Review (Advanced Course: Module 6 Appendix)
Expert Medical Opinion Program
Ron D. Hays August 5, 2011 (12:16-12:24pm) 6 minutes presentation + 3 minutes questions.
An App Supporting Psoriasis Patients Improves Adherence to Topical Treatment: A randomised controlled trial M.T. Svendsen,1,2,3 F. Andersen,1,4 K.H. Andersen,4.
Journal editor perspectives
ISSUES RELATED TO PUBLICATION OF health system-based investigations
Expert Medical Opinion Program
Introduction to Systematic Reviews
Presentation transcript:

Journal Editor Perspectives Digital Health Learning & Clinical Effectiveness Research Collaboratives Journal Editor Perspectives May 22, 2019 Joseph S. Ross, MD, MHS Section of General Internal Medicine, School of Medicine Center for Outcomes Research and Evaluation, Yale-New Haven Hospital Associate Editor, JAMA Internal Medicine Former Deputy Editor, Journal of General Internal Medicine

Source: Grady, Redberg and O’Malley JAMA Internal Medicine 2018;178:187.

Observational Research Studies Studies using data from clinical registries, administrative claims, electronic health records Increasingly, medical product evaluations … … but also quality improvement studies, health system innovations, policy evaluations, and more. Source: Corrigan-Curay et. al., JAMA 2018;320:867-868. Califf et. al., NEJM 2016;375:2395-2400.

Special Considerations Generalizability: Single system vs. multiple systems What can be learned from single system evaluations? Intervention and Control Groups: How defined? Accounting for non-random treatment allocation Effectiveness and Safety Endpoints: How ascertained? Codes accurate and clinically meaningful? Over what period of follow-up? Negative “control” endpoint? Study protocol / registration? Public pre-specification of data source; inclusion/exclusion criteria; primary, secondary and safety endpoints; and statistical analysis plan.